Peroxisome biogenesis disorder 2b is a rare genetic condition that affects how cells handle fats and detoxify substances. Features often start in infancy and can include low muscle tone, feeding problems, vision or hearing loss, and developmental delay. Some children have seizures, liver disease, bone changes, or problems with growth. The condition is lifelong and severity varies, and for some it can shorten life, especially in early childhood. Care focuses on supportive treatment such as seizure control, nutrition support, hearing and vision care, and monitoring of liver, bones, and growth.
Overview
Peroxisome biogenesis disorder 2bSymptoms
Peroxisome biogenesis disorder 2b usually shows in newborns with weak muscle tone, poor feeding, breathing problems, and seizures. Other features include enlarged liver, jaundice, vision and hearing loss, distinctive facial features, and profound developmental delay.
Outlook and prognosis
Many living with Peroxisome biogenesis disorder 2b face developmental delays, low muscle tone, feeding challenges, and vision or hearing loss that start in infancy. Severity varies widely; some children have life‑limiting complications, while others achieve partial milestones. Early supportive care, nutrition, seizure control, and vision/hearing therapies can improve comfort and day‑to‑day function.
Causes and risk factors
Peroxisome biogenesis disorder 2b results from inherited changes in peroxisome-related genes, usually autosomal recessive. Risk is higher when both parents are carriers or are closely related. Environmental or lifestyle factors don’t cause it but may influence complications and overall health.
Genetic influences
Genetics is central in Peroxisome biogenesis disorder 2b. Variants in PEX genes disrupt peroxisome formation, typically inherited in an autosomal recessive pattern. Specific genetic changes influence severity, age at onset, organ involvement, and prognosis, guiding testing, counseling, and family planning.
Diagnosis
Doctors suspect Peroxisome biogenesis disorder 2b from early clinical features and lab markers. Genetic tests confirming PEX gene changes provide the genetic diagnosis of Peroxisome biogenesis disorder 2b; imaging and metabolic studies support the diagnosis and assess severity.
Treatment and drugs
Treatment for peroxisome biogenesis disorder 2b focuses on supportive, multidisciplinary care. Teams often use seizure medicines, nutrition support (including feeding assistance and fat‑soluble vitamins), vision and hearing aids, and targeted therapies for liver, adrenal, and breathing issues. Regular monitoring guides adjustments as needs change.
Symptoms
Peroxisome biogenesis disorder 2b often shows up in infancy with low muscle tone, feeding trouble, and slower development. Early on, this might look like a baby who feels unusually floppy, tires quickly while feeding, or is harder to rouse between naps. Early features of Peroxisome biogenesis disorder 2b often include vision or hearing concerns and slow developmental progress. Features can range from mild to more pronounced, and needs often change over time.
Babies may feel unusually floppy and have delayed head control. Clinicians call this hypotonia, which means muscles provide less support for movement and posture.
Many infants with Peroxisome biogenesis disorder 2b have a weak suck, tire during feeds, or spit up often. This can make weight gain slower than expected.
Milestones like rolling, sitting, and babbling can take longer. In medical terms, this is developmental delay; in everyday life, it shows up as skills arriving later than peers.
Some children with Peroxisome biogenesis disorder 2b have episodes of stiffening, jerking, or staring spells. A healthcare team can confirm seizures and guide treatment.
How people usually first notice Peroxisome biogenesis disorder 2b?
Many families first notice something is different in the first weeks or months of life, when a baby with peroxisome biogenesis disorder 2b may have very low muscle tone (feels “floppy”), feeding difficulties, poor weight gain, or seizures. Doctors may also spot early clues such as unusual facial features, liver enlargement, vision or hearing concerns, or developmental delays during newborn exams, imaging, or routine checkups, which then prompt metabolic and genetic testing. In some cases, the first signs of peroxisome biogenesis disorder 2b are picked up prenatally on ultrasound, such as growth restriction or organ differences, leading to further evaluation after birth.
Types of Peroxisome biogenesis disorder 2b
Peroxisome biogenesis disorder 2b is a genetic condition with a spectrum of severity rather than a single uniform presentation. Clinicians often describe them in these categories: classic neonatal forms, intermediate childhood-onset forms, and milder adolescent–adult presentations. These variants reflect how strongly peroxisome function is affected by the underlying PEX gene changes, which in turn shapes early symptoms and long‑term needs. People may notice different sets of symptoms depending on their situation, so reading about types of Peroxisome biogenesis disorder 2b can clarify what to expect day to day.
Classic neonatal form
Symptoms begin at birth or soon after with feeding trouble, low muscle tone, and vision or hearing concerns. Doctors may see characteristic facial features, enlarged liver, and bone changes on imaging. Development is typically severely delayed.
Intermediate childhood-onset
Symptoms appear in early childhood with slower development, low muscle tone, and progressive vision or hearing loss. Growth may be below average, and liver or bone findings can emerge over time. Children often gain some skills but may lose abilities later.
Mild adolescent–adult
Symptoms are milder, with later onset hearing or vision problems and subtle coordination or learning challenges. Liver and bone issues are less prominent or develop slowly. Many keep everyday independence but may need targeted supports.
Neurologic‑predominant
Movement, tone, and developmental delays stand out more than other features. Seizures or coordination problems may be the main drivers of daily difficulties. Other organs can be involved but to a lesser degree.
Hepatic‑skeletal‑predominant
Liver enlargement, liver function changes, and characteristic bone findings are more noticeable. Growth issues and joint stiffness may affect mobility and comfort. Neurologic symptoms are present but comparatively milder.
What genetics can tell you about symptoms
Some people with peroxisome biogenesis disorder 2b (PBD2B), caused by PEX10 gene changes, develop weak muscle tone, feeding difficulties, hearing or vision loss, and seizures. These variants disrupt peroxisomes—cell “cleanup and fat-processing” hubs—leading to toxic buildup and nerve, liver, and bone problems.
Causes and risk factors
Peroxisome biogenesis disorder 2b happens when both copies of a PEX gene have harmful changes. Some risks are written in our DNA, passed down through families. It is usually autosomal recessive, so two healthy carriers have a 25% chance in each pregnancy. Risk factors for Peroxisome biogenesis disorder 2b include having carrier parents or parents who are related by blood. Lifestyle or environment do not cause it, but infections or other illnesses can make symptoms more noticeable.
Environmental and biological risk factors
Peroxisome biogenesis disorder 2b begins very early in development, and for most families there are no clear environmental triggers. Doctors often group risks into internal (biological) and external (environmental). Here, we focus on environmental and biological risk factors for peroxisome biogenesis disorder 2b and what is, and is not, known. This helps set expectations about which exposures matter and which likely do not.
There are no established environmental exposures that raise the risk of peroxisome biogenesis disorder 2b. Broad toxins can harm fetal development, but they have not been shown to trigger this specific condition.
New changes in egg or sperm become more common as parents get older. Current research does not show a clear connection between parental age and this diagnosis.
Severe, uncontrolled illnesses in pregnancy can affect fetal growth and organ formation. They are not known to increase the chance of peroxisome biogenesis disorder 2b.
Intense radiation or certain industrial chemicals can damage reproductive cells or an early embryo. Evidence linking such exposures to this condition is lacking.
Genetic risk factors
Families sometimes notice early symptoms of Peroxisome biogenesis disorder 2b soon after birth, but the underlying cause is genetic. Most cases stem from harmful changes in a single gene, PEX5, which prevents peroxisomes—small compartments in cells—from working properly. Carrying a genetic change doesn’t guarantee the condition will appear. The condition follows an autosomal recessive pattern, meaning most children inherit one nonworking copy from each healthy carrier parent.
PEX5 gene variants: Harmful changes (variants) in the PEX5 gene are the main known cause of Peroxisome biogenesis disorder 2b. PEX5 helps peroxisomes bring needed enzymes inside; when it falters, these cell compartments cannot work properly. Many different PEX5 variants have been found across families.
Autosomal recessive pattern: Peroxisome biogenesis disorder 2b happens when a child inherits two nonworking PEX5 copies, one from each parent. Parents with a single nonworking copy are healthy carriers. Each pregnancy between two carriers has a 25% (1 in 4) chance of an affected child.
Compound heterozygosity: Many people have two different PEX5 changes rather than the same change twice. The exact combination can alter how much PEX5 still works, which can influence severity. Even in the same family, symptoms and timing can differ.
Variant diversity: Dozens of PEX5 changes exist in different populations. Some changes stop the gene entirely, while others only reduce its activity. People with the same risk factor can have very different experiences.
Founder effects: In some communities, a specific PEX5 change may be more common because of shared ancestry. This can increase the chance that two carriers meet and have a child with the condition. Genetic counseling can clarify carrier status in families from these groups.
Shared family background: When parents are from the same extended family, they are more likely to carry the same rare PEX5 change. This increases the likelihood of Peroxisome biogenesis disorder 2b in a child. Carrier testing can refine personal risk.
Lifestyle risk factors
Peroxisome biogenesis disorder 2b is a genetic condition; lifestyle habits do not cause it but can shape day-to-day symptoms, complications, and quality of life. Understanding how lifestyle affects Peroxisome biogenesis disorder 2b can help families focus on supportive routines that reduce preventable problems. Below are practical elements that link behaviors to specific outcomes in this condition.
Upright positioning and texture-appropriate or thickened feeds can lower aspiration and pneumonia risk. Small, frequent, high-calorie meals can support growth when hypotonia and poor suck limit intake.
Clinician-guided fat-soluble vitamin support and caloric boosters can offset malabsorption from liver involvement. Maintaining adequate protein and energy helps immune function and recovery from illness.
Sleep deprivation can lower seizure threshold and worsen irritability. A regular sleep schedule may reduce breakthrough seizures and daytime fatigue.
Gentle daily range-of-motion and supported positioning help prevent contractures and scoliosis. Assisted airway clearance techniques can improve breathing efficiency and reduce respiratory infections.
Risk prevention
Peroxisome biogenesis disorder 2b is a genetic condition present from birth, so we cannot prevent the condition itself. Prevention focuses on lowering complications, finding problems early, and supporting comfort and development. Some prevention is universal, others are tailored to people with specific risks. Learning early symptoms of peroxisome biogenesis disorder 2b and staying on top of care can reduce hospital stays and improve quality of life.
A genetics professional can explain inheritance and the chance of PBD2b in future pregnancies. They can also review testing options for relatives.
Carrier testing, IVF with embryo testing, or prenatal testing can lower the chance of having another child with PBD2b. Your care team can guide which option fits your values and health needs.
Seeing a metabolic or genetics clinic early helps map out monitoring and treatment for PBD2b. A written care plan can prevent delays if urgent issues arise.
Routine vaccines lower the risk of severe infections that can hit children with PBD2b harder. Annual flu shots and COVID-19 vaccination are usually recommended; ask your clinician about timing.
Transmission
Peroxisome biogenesis disorder 2b is a genetic condition and isn’t infectious—you can’t catch or spread it through everyday contact. The genetic transmission of Peroxisome biogenesis disorder 2b is autosomal recessive: a child is affected only when they inherit two nonworking copies of the same gene, one from each parent. Parents who each carry one nonworking copy usually have no symptoms, and with every pregnancy there is a 25% (1 in 4) chance of an affected child, a 50% (1 in 2) chance of a carrier child, and a 25% (1 in 4) chance of a child who is neither. If you’re wondering how Peroxisome biogenesis disorder 2b is inherited in your family, a genetic counselor can explain your specific risks and discuss carrier, prenatal, or preimplantation testing.
When to test your genes
Consider testing if you or a child show early signs like low muscle tone, vision or hearing loss, liver problems, or developmental delays, especially in infancy. Genetic testing is also appropriate if a sibling is affected or both parents are known carriers, to confirm diagnosis and guide care. Prenatal or preimplantation testing may be considered in future pregnancies with known familial variants.
Diagnosis
Peroxisome biogenesis disorder 2b is usually identified early in life based on a pattern of symptoms and lab clues. Doctors usually begin with a careful review of symptoms, growth, and development. Because this is an inherited condition within the Zellweger spectrum, the genetic diagnosis of Peroxisome biogenesis disorder 2b is confirmed with specific tests. Early testing helps guide care plans and supports for feeding, vision, hearing, and development.
A pediatrician looks for low muscle tone, feeding problems, seizures, and distinctive facial or skeletal features. Liver enlargement, jaundice, or developmental delays can raise suspicion for a peroxisomal disorder.
Blood tests check very long-chain fatty acids and related markers that build up when peroxisomes don’t work well. Abnormal results support a diagnosis of a Zellweger spectrum disorder.
Sequencing looks for disease-causing changes in PEX genes, including PEX5, to confirm Peroxisome biogenesis disorder 2b. Genetic testing may be offered to clarify risk or guide treatment.
A small skin sample can be used to grow cells and measure peroxisome function directly. These tests can show impaired fatty acid breakdown or reduced plasmalogen production when blood results are unclear.
Stages of Peroxisome biogenesis disorder 2b
Peroxisome biogenesis disorder 2b does not have defined progression stages. The condition falls along a wide spectrum, so early symptoms of Peroxisome biogenesis disorder 2b and how quickly they change can vary a lot from one child to another rather than following set steps. Different tests may be suggested to help confirm what’s going on, including blood work that looks at certain fatty acids, imaging, and checks of vision, hearing, liver function, and development. A molecular diagnosis with genetic testing can confirm the subtype and guide monitoring over time with regular specialist visits.
Outlook and prognosis
Looking at the long-term picture can be helpful. Peroxisome biogenesis disorder 2b (PBD2b) often starts early, and families may first notice slow motor milestones, low muscle tone, feeding difficulties, vision or hearing changes, or seizures. Many people ask, “What does this mean for my future?”, and the answer depends on how severe the features are at the start and how quickly they change over time. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Early symptoms of Peroxisome biogenesis disorder 2b that include significant feeding issues, breathing problems, or difficult-to-control seizures generally point to a more complex course, while milder symptoms can be compatible with longer survival and more day-to-day independence.
Prognosis refers to how a condition tends to change or stabilize over time. For many living with PBD2b, development progresses but at a slower pace, and there can be periods of stability punctuated by setbacks during illness or growth spurts. Some people experience vision and hearing loss that worsen, while others notice these changes level off for a time. Liver dysfunction, adrenal hormone issues, and bone or dental problems may appear later, so regular monitoring matters. With ongoing care, many people maintain comfort and meaningful routines at home, though some will need wheelchair support, feeding tubes, or breathing aids as needs evolve.
Even though it can feel overwhelming, early care can make a real difference in quality of life and safety. Survival varies: children with more severe forms may face life-limiting complications in infancy or early childhood, while those with intermediate or milder PBD2b can live into later childhood, adolescence, or adulthood. Support from friends and family can strengthen coping and keep therapies on track. Talk with your doctor about what your personal outlook might look like, including how genetic test results, organ involvement, and response to treatments may guide expectations over time.
Long-term effects
Peroxisome biogenesis disorder 2b is a genetic condition with long-term effects that can touch movement, learning, senses, and overall health. Long-term effects vary widely, with some children having severe needs and others following a slower-changing course. Some families first notice early symptoms of Peroxisome biogenesis disorder 2b in infancy, but the long-term picture becomes clearer over time. For some, health complications can shorten lifespan, while others may live into later childhood or adulthood, depending on severity.
Ongoing developmental delays and learning differences are common. Many need extra support with communication and daily skills over time.
Low muscle tone in infancy may shift toward stiffness or coordination problems later. This can affect walking, balance, and fine motor skills in Peroxisome biogenesis disorder 2b.
Seizures may begin early and can persist or change over time. They can influence alertness, development, and daily routines.
Progressive retinal problems can lead to poor night vision and gradual vision loss. Some develop cataracts or optic nerve changes associated with Peroxisome biogenesis disorder 2b.
How is it to live with Peroxisome biogenesis disorder 2b?
Living with peroxisome biogenesis disorder 2b often means navigating complex medical needs from infancy, with frequent appointments, therapies, and careful coordination of feeding, breathing, seizure control, and comfort. Many families build their days around supportive care—positioning to prevent contractures, managing nutrition, monitoring for infections, and using adaptive equipment—while celebrating small signals of connection like eye contact or a calm moment. For siblings, relatives, and caregivers, the emotional load can be heavy and constant, yet many also describe a tight-knit routine and a strong care team that helps them feel less alone. Planning ahead for respite care, clear communication with clinicians, and connecting with other families can make daily life more manageable and more supported.
Treatment and drugs
Peroxisome biogenesis disorder 2b is treated with supportive care focused on easing symptoms, protecting organs, and improving comfort, since no curative therapy currently exists. Care teams often include neurology, genetics, ophthalmology, audiology, rehabilitation, nutrition, and gastroenterology to address seizures, movement issues, feeding difficulties, vision and hearing changes, liver disease, and adrenal insufficiency. Seizures are typically managed with antiseizure medicines; feeding problems may call for high-calorie formulas or a feeding tube; and hormone replacement can treat low adrenal function, while regular eye and ear assessments guide glasses, hearing aids, or cochlear implants. Alongside medical treatment, lifestyle choices play a role, including physical, occupational, and speech therapy to support mobility, communication, and daily activities, plus vaccinations and prompt infection care. Research is ongoing into gene- and cell-based approaches; ask your doctor about the best starting point for you.
Non-drug treatment
Daily life with Peroxisome biogenesis disorder 2b often involves supporting feeding, breathing, movement, and communication. Alongside medicines, non-drug therapies can support comfort, growth, and development. Plans are tailored to each child and may change as needs evolve. A coordinated team helps families focus on practical skills at home and in the community.
Gentle stretching and positioning help prevent stiff joints and contractures. Therapists also work on head control, posture, and safe ways to move or transfer.
Training focuses on daily activities like feeding, dressing, and play. Splints, specialized seating, and simple home adaptations can make care easier.
Swallow therapy assesses safety and reduces choking or aspiration risk. Communication supports—such as picture boards or devices—help express needs.
A dietitian can tailor calories, textures, and feeding schedules to support growth. If oral feeding is unsafe or too tiring, tube feeding through a gastrostomy may be considered.
Your genes may have an impact on how drugs work for you
Medicines for peroxisome biogenesis disorder 2b can work differently depending on gene changes that affect how cells handle fats, bile acids, and oxidative stress. Genetic testing can guide dosing and choice of supplements like bile acid therapy or antioxidants.
Pharmacological treatments
Medicines for Peroxisome biogenesis disorder 2b focus on easing symptoms and protecting organs like the liver, brain, and gut rather than curing the condition. Some drugs may be started when early symptoms of Peroxisome biogenesis disorder 2b appear, such as seizures or poor weight gain. Not everyone responds to the same medication in the same way. Your medical team will tailor choices to age, liver function, and the specific challenges your child is facing.
This bile acid can improve fat absorption and ease liver stress in peroxisomal disorders. Doctors monitor liver tests and adjust dosing as your child grows.
Extra vitamins A, D, E, and K support growth, bone health, vision, and blood clotting. Levels are checked regularly to avoid both deficiency and excess.
Levetiracetam or clobazam are commonly used to reduce seizures. Valproate is often avoided because it can strain the liver.
Proton pump inhibitors like omeprazole or esomeprazole, or the H2‑blocker famotidine, can reduce stomach acid. This may improve feeding comfort and weight gain.
Genetic influences
Peroxisome biogenesis disorder 2b stems from changes in genes that are needed to make peroxisomes, the small compartments in cells that break down certain fats and help clear harmful byproducts. When these genes—often called PEX genes—don’t work as they should, peroxisomes can’t form or function properly, which drives the features of the condition. The condition follows an autosomal recessive pattern: typically both parents carry one nonworking copy of the gene, and with each pregnancy there is a 25% (1 in 4) chance of having a child with Peroxisome biogenesis disorder 2b. A “carrier” means you hold the gene change but may not show symptoms. Different variants in these genes can act like stronger or weaker dimmer switches, so the age at presentation and early symptoms of Peroxisome biogenesis disorder 2b can vary from one child to another. Targeted genetic testing can identify the exact gene change, confirm the diagnosis, and help clarify risks for future pregnancies and for other relatives.
Is Peroxisome biogenesis disorder 2b genetic?
Genetics is central in Peroxisome biogenesis disorder 2b. Variants in PEX genes disrupt peroxisome formation, typically inherited in an autosomal recessive pattern. Specific genetic changes influence severity, age at onset, organ involvement, and prognosis, guiding testing, counseling, and family planning.
Pharmacogenetics—how genetics influence drug effects
For people with Peroxisome biogenesis disorder 2b, medication choice and dose are shaped by how the condition affects the liver, bile flow, and the body’s handling of fats. Because peroxisomes help process very long‑chain fats, the genetic change can lower absorption of fat‑soluble drugs and vitamins and make the liver more sensitive to side effects, so doctors often choose medicines with gentler liver profiles and adjust doses based on regular lab checks. Seizure medicines are frequently needed; some, such as valproate, can stress the liver in infants and children, so teams may avoid them or monitor closely, and they may prefer options with fewer liver demands. Cholic acid and fat‑soluble vitamin supplements are sometimes used; response tends to track with overall disease severity and liver health rather than a specific drug–gene match. Not every difference in response is genetic, but understanding common drug–gene patterns may help tailor certain anti‑seizure or mood medicines when they are part of care. In practice, pharmacogenetic testing in Peroxisome biogenesis disorder 2b can complement clinical judgment, especially if multiple medications are being tried or side effects appear early.
Interactions with other conditions
In Peroxisome biogenesis disorder 2b, common coexisting issues like chest infections, feeding difficulties, epilepsy, and liver trouble can influence each other and make everyday symptoms feel heavier. Doctors call it a “comorbidity” when two conditions occur together. A simple cold or lower respiratory infection can worsen breathing and raise seizure risk, while reflux increases the chance of aspiration pneumonia. Liver involvement in Peroxisome biogenesis disorder 2b may change how medicines are processed, so treatments for seizures or infections often need careful dosing and monitoring. Early symptoms of Peroxisome biogenesis disorder 2b can overlap with neonatal infections or other metabolic illnesses, which can delay targeted care. Hearing and vision loss may compound developmental challenges, and poor absorption of vitamins A, D, E, and K can make bone or bleeding problems from other illnesses more noticeable.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described infants who struggled with feeding, had poor muscle tone, trouble with vision and hearing, and did not reach early milestones. Families and communities once noticed patterns that some newborns in the same extended family were more severely affected, while others had milder issues that only became clear later in childhood. These lived observations hinted at an inherited condition long before lab testing existed.
From early theories to modern research, the story of Peroxisome biogenesis disorder 2b (PBD 2b) reflects how medicine learns by connecting clues. In the mid to late 20th century, doctors grouped several severe newborn conditions—marked by low muscle tone, seizures, and distinctive facial features—under umbrella names like the Zellweger spectrum. At first, the grouping was based on what could be seen and measured: developmental delays, liver enlargement, vision problems, and very long–chain fats building up in blood tests. As biochemical testing improved, clinicians realized these conditions shared a breakdown in tiny cell parts called peroxisomes, which normally help process certain fats and support brain and eye development.
With each decade, scientists moved from the lab bench to the gene level. Researchers identified “PEX” genes that act like a coordinated team to assemble working peroxisomes. One of these, now known as PEX3, became linked to a specific form within the spectrum—what is medically called peroxisome biogenesis disorder type 2b. This shift—from classifying by symptoms to pinpointing the exact gene—helped explain why some babies have a rapidly progressive course while others, with different gene changes in the same pathway, have a slower, milder pattern.
Advances in genetics confirmed what families had suspected: PBD 2b follows an autosomal recessive pattern, meaning each parent typically carries one silent change in the gene. Over time, descriptions became more precise. Newborn screening panels in some regions began to catch abnormal fat markers early; imaging and eye exams documented the range of features; and genetic testing allowed clear diagnosis without waiting for all symptoms to appear.
Not every early description was complete, yet together they built the foundation of today’s knowledge. The modern picture of PBD 2b combines careful clinical observation, specialized blood tests, and DNA analysis to provide answers sooner. This history explains why you may see older terms like “Zellweger spectrum disorder” alongside gene-based names in medical records. It also underlines a key lesson: the same pathway can lead to different experiences, and naming the exact gene change helps tailor care, guide family planning, and connect people with the right support.